- $41.98m
- $153.71m
- $29.62m
- 42
- 44
- 87
- 60
Annual balance sheet for Fibrogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 687 | 405 | 422 | 236 | 50.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 41.9 | 25.4 | 16.3 | 41.1 | 29 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 755 | 474 | 493 | 332 | 197 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 65.3 | 120 | 101 | 81.4 | 0.097 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 827 | 774 | 610 | 424 | 215 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 163 | 225 | 274 | 218 | 133 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 405 | 565 | 632 | 628 | 440 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 422 | 209 | -21.4 | -204 | -226 |
| Total Liabilities & Shareholders' Equity | 827 | 774 | 610 | 424 | 215 |
| Total Common Shares Outstanding |